Ubs Asset Management Americas Inc Rhythm Pharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 125,782 shares of RYTM stock, worth $10.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
125,782
Previous 218,544
42.45%
Holding current value
$10.9 Million
Previous $12.2 Million
45.46%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding RYTM
# of Institutions
248Shares Held
63MCall Options Held
403KPut Options Held
62.8K-
Black Rock Inc. New York, NY6.74MShares$583 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.08MShares$526 Million6.69% of portfolio
-
Primecap Management CO Pasadena, CA5.79MShares$500 Million0.26% of portfolio
-
Baker Bros. Advisors LP New York, NY5.6MShares$485 Million3.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.44MShares$298 Million0.0% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $4.82B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...